Skip to content
2000
Volume 22, Issue 1
  • ISSN: 1875-6921
  • E-ISSN: 1875-6913

Abstract

Background/Introduction

Lung cancer (LC) is a lethal malignancy with a late diagnosis and poor prognosis. During the last decade, the identification of oncogenic driver alterations has noticeably changed the therapeutic landscape and contributed to the emergence of the “oncogene addiction” concept and precision medicine in oncology. Among these alterations, the spotlight has turned to driver mutations in the and genes, which have garnered significant attention due to the emergence of targeted therapies and the potential for personalized treatment strategies.

Objective

Hence, the present study aimed to evaluate the mutational landscape of the and genes in LC Moroccan patients along with their frequencies and their correlation with clinicopathological features.

Methods

A total of 60 fresh biopsies were collected from patients with primary LC and were subjected to PCR-DNA sequencing of exon 2 of and exon 15 of genes in order to detect the most common mutations known by their implication in response to targeted therapies.

Results and Discussion

Sequencing analysis revealed that mutations in and genes represented respectively 8.3% and 6.7% of cases; one patient had two mutations (G12A and K5E), and none had simultaneous and mutations. The vast majority of patients harboring mutations were men, formal smokers with adenocarcinomas, and at advanced stage (stage III). mutations were mainly detected in men and non-smokers with adenocarcinoma. Statistical analyses showed no significant correlation between and substitutions and clinico-pathological features (>0.05).

Conclusion

The presence of these mutations will be used as a valuable molecular biomarker to select potential candidates eligible for effective personalized therapy using available agents targeting these mutations. However, much effort is needed to identify other druggable mutations to generalize personalized LC therapy for better management of this devastating disease.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cppm/10.2174/0118756921347352241112105112
2024-12-03
2025-09-05

  • From This Site

    /content/journals/cppm/10.2174/0118756921347352241112105112
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global Cancer Statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  2. El FouniniY. ChaouiI. DehbiH. El MzibriM. AbounaderR. GuessousF. MicroRNAs: Key regulators in lung cancer.MicroRNA202110210912210.2174/221153661066621052710252234047262
     [Google Scholar]
  3. BrayF. FerlayJ. SoerjomataramI. SiegelR.L. TorreL.A. JemalA. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.201868639442410.3322/caac.2149230207593
     [Google Scholar]
  4. GuoQ. LiuL. ChenZ. FanY. ZhouY. YuanZ. ZhangW. Current treatments for non-small cell lung cancer.Front. Oncol.20221294510210.3389/fonc.2022.94510236033435
     [Google Scholar]
  5. KönigD. Savic PrinceS. RothschildS.I. Targeted therapy in advanced and metastatic non-small cell lung cancer. an update on treatment of the most important actionable oncogenic driver alterations.Cancers (Basel)202113480410.3390/cancers1304080433671873
     [Google Scholar]
  6. CeddiaS. LandiL. CappuzzoF. KRAS-mutant non-small-cell lung cancer: from past efforts to future challenges.Int. J. Mol. Sci.20222316939110.3390/ijms2316939136012655
     [Google Scholar]
  7. CascettaP. MarinelloA. LazzariC. GregorcV. PlanchardD. BiancoR. NormannoN. MorabitoA. KRAS in NSCLC: State of the Art and Future Perspectives.Cancers (Basel)20221421543010.3390/cancers1421543036358848
     [Google Scholar]
  8. Sanchez-VegaF. MinaM. ArmeniaJ. ChatilaW.K. LunaA. LaK.C. DimitriadoyS. LiuD.L. KanthetiH.S. SaghafiniaS. ChakravartyD. DaianF. GaoQ. BaileyM.H. LiangW.W. FoltzS.M. ShmulevichI. DingL. HeinsZ. OchoaA. GrossB. GaoJ. ZhangH. KundraR. KandothC. BahceciI. DervishiL. DogrusozU. ZhouW. ShenH. LairdP.W. WayG.P. GreeneC.S. LiangH. XiaoY. WangC. IavaroneA. BergerA.H. BivonaT.G. LazarA.J. HammerG.D. GiordanoT. KwongL.N. McArthurG. HuangC. TwardA.D. FrederickM.J. McCormickF. MeyersonM. Van AllenE.M. CherniackA.D. CirielloG. SanderC. SchultzN. Caesar-JohnsonS.J. DemchokJ.A. FelauI. KasapiM. FergusonM.L. HutterC.M. SofiaH.J. TarnuzzerR. WangZ. YangL. ZenklusenJ.C. ZhangJ.J. ChudamaniS. LiuJ. LollaL. NareshR. PihlT. SunQ. WanY. WuY. ChoJ. DeFreitasT. FrazerS. GehlenborgN. GetzG. HeimanD.I. KimJ. LawrenceM.S. LinP. MeierS. NobleM.S. SaksenaG. VoetD. ZhangH. BernardB. ChambweN. DhankaniV. KnijnenburgT. KramerR. LeinonenK. LiuY. MillerM. ReynoldsS. ShmulevichI. ThorssonV. ZhangW. AkbaniR. BroomB.M. HegdeA.M. JuZ. KanchiR.S. KorkutA. LiJ. LiangH. LingS. LiuW. LuY. MillsG.B. NgK-S. RaoA. RyanM. WangJ. WeinsteinJ.N. ZhangJ. AbeshouseA. ArmeniaJ. ChakravartyD. ChatilaW.K. de BruijnI. GaoJ. GrossB.E. HeinsZ.J. KundraR. LaK. LadanyiM. LunaA. NissanM.G. OchoaA. PhillipsS.M. ReznikE. Sanchez-VegaF. SanderC. SchultzN. SheridanR. SumerS.O. SunY. TaylorB.S. WangJ. ZhangH. AnurP. PetoM. SpellmanP. BenzC. StuartJ.M. WongC.K. YauC. HayesD.N. ParkerJ.S. WilkersonM.D. AllyA. BalasundaramM. BowlbyR. BrooksD. CarlsenR. ChuahE. DhallaN. HoltR. JonesS.J.M. KasaianK. LeeD. MaY. MarraM.A. MayoM. MooreR.A. MungallA.J. MungallK. RobertsonA.G. SadeghiS. ScheinJ.E. SipahimalaniP. TamA. ThiessenN. TseK. WongT. BergerA.C. BeroukhimR. CherniackA.D. CibulskisC. GabrielS.B. GaoG.F. HaG. MeyersonM. SchumacherS.E. ShihJ. KucherlapatiM.H. KucherlapatiR.S. BaylinS. CopeL. DanilovaL. BootwallaM.S. LaiP.H. MaglinteD.T. Van Den BergD.J. WeisenbergerD.J. AumanJ.T. BaluS. BodenheimerT. FanC. HoadleyK.A. HoyleA.P. JefferysS.R. JonesC.D. MengS. MieczkowskiP.A. MoseL.E. PerouA.H. PerouC.M. RoachJ. ShiY. SimonsJ.V. SkellyT. SolowayM.G. TanD. VeluvoluU. FanH. HinoueT. LairdP.W. ShenH. ZhouW. BellairM. ChangK. CovingtonK. CreightonC.J. DinhH. DoddapaneniH.V. DonehowerL.A. DrummondJ. GibbsR.A. GlennR. HaleW. HanY. HuJ. KorchinaV. LeeS. LewisL. LiW. LiuX. MorganM. MortonD. MuznyD. SantibanezJ. ShethM. ShinbrotE. WangL. WangM. WheelerD.A. XiL. ZhaoF. HessJ. AppelbaumE.L. BaileyM. CordesM.G. DingL. FronickC.C. FultonL.A. FultonR.S. KandothC. MardisE.R. McLellanM.D. MillerC.A. SchmidtH.K. WilsonR.K. CrainD. CurleyE. GardnerJ. LauK. MalleryD. MorrisS. PaulauskisJ. PennyR. SheltonC. SheltonT. ShermanM. ThompsonE. YenaP. BowenJ. Gastier-FosterJ.M. GerkenM. LeraasK.M. LichtenbergT.M. RamirezN.C. WiseL. ZmudaE. CorcoranN. CostelloT. HovensC. CarvalhoA.L. de CarvalhoA.C. FregnaniJ.H. Longatto-FilhoA. ReisR.M. Scapulatempo-NetoC. SilveiraH.C.S. VidalD.O. BurnetteA. EschbacherJ. HermesB. NossA. SinghR. AndersonM.L. CastroP.D. IttmannM. HuntsmanD. KohlB. LeX. ThorpR. AndryC. DuffyE.R. LyadovV. PaklinaO. SetdikovaG. ShabuninA. TavobilovM. McPhersonC. WarnickR. BerkowitzR. CramerD. FeltmateC. HorowitzN. KibelA. MutoM. RautC.P. MalykhA. Barnholtz-SloanJ.S. BarrettW. DevineK. FulopJ. OstromQ.T. ShimmelK. WolinskyY. SloanA.E. De RoseA. GiulianteF. GoodmanM. KarlanB.Y. HagedornC.H. EckmanJ. HarrJ. MyersJ. TuckerK. ZachL.A. DeyarminB. HuH. KvecherL. LarsonC. MuralR.J. SomiariS. VichaA. ZelinkaT. BennettJ. IacoccaM. RabenoB. SwansonP. LatourM. LacombeL. TêtuB. BergeronA. McGrawM. StaugaitisS.M. ChabotJ. HibshooshH. SepulvedaA. SuT. WangT. PotapovaO. VoroninaO. DesjardinsL. MarianiO. Roman-RomanS. SastreX. SternM-H. ChengF. SignorettiS. BerchuckA. BignerD. LippE. MarksJ. McCallS. McLendonR. SecordA. SharpA. BeheraM. BratD.J. ChenA. DelmanK. ForceS. KhuriF. MaglioccaK. MaithelS. OlsonJ.J. OwonikokoT. PickensA. RamalingamS. ShinD.M. SicaG. Van MeirE.G. ZhangH. EijckenboomW. GillisA. KorpershoekE. LooijengaL. OosterhuisW. StoopH. van KesselK.E. ZwarthoffE.C. CalatozzoloC. CuppiniL. CuzzubboS. DiMecoF. FinocchiaroG. MatteiL. PerinA. PolloB. ChenC. HouckJ. LohavanichbutrP. HartmannA. StoehrC. StoehrR. TaubertH. WachS. WullichB. KyclerW. MurawaD. WiznerowiczM. ChungK. EdenfieldW.J. MartinJ. BaudinE. BubleyG. BuenoR. De RienzoA. RichardsW.G. KalkanisS. MikkelsenT. NoushmehrH. ScarpaceL. GirardN. AymerichM. CampoE. GinéE. GuillermoA.L. Van BangN. HanhP.T. PhuB.D. TangY. ColmanH. EvasonK. DottinoP.R. MartignettiJ.A. GabraH. JuhlH. AkeredoluT. StepaS. HoonD. AhnK. KangK.J. BeuschleinF. BreggiaA. BirrerM. BellD. BoradM. BryceA.H. CastleE. ChandanV. ChevilleJ. CoplandJ.A. FarnellM. FlotteT. GiamaN. HoT. KendrickM. KocherJ-P. KoppK. MoserC. NagorneyD. O’BrienD. O’NeillB.P. PatelT. PetersenG. QueF. RiveraM. RobertsL. SmallridgeR. SmyrkT. StantonM. ThompsonR.H. TorbensonM. YangJ.D. ZhangL. BrimoF. AjaniJ.A. GonzalezA.M.A. BehrensC. BondarukJ. BroaddusR. CzerniakB. EsmaeliB. FujimotoJ. GershenwaldJ. GuoC. LazarA.J. LogothetisC. Meric-BernstamF. MoranC. RamondettaL. RiceD. SoodA. TamboliP. ThompsonT. TroncosoP. TsaoA. WistubaI. CarterC. HayduL. HerseyP. JakrotV. KakavandH. KeffordR. LeeK. LongG. MannG. QuinnM. SawR. ScolyerR. ShannonK. SpillaneA. StretchJ. SynottM. ThompsonJ. WilmottJ. Al-AhmadieH. ChanT.A. GhosseinR. GopalanA. LevineD.A. ReuterV. SingerS. SinghB. TienN.V. BroudyT. MirsaidiC. NairP. DrwiegaP. MillerJ. SmithJ. ZarenH. ParkJ-W. HungN.P. KebebewE. LinehanW.M. MetwalliA.R. PacakK. PintoP.A. SchiffmanM. SchmidtL.S. VockeC.D. WentzensenN. WorrellR. YangH. MoncrieffM. GoparajuC. MelamedJ. PassH. BotnariucN. CaramanI. CernatM. ChemencedjiI. ClipcaA. DorucS. GorincioiG. MuraS. PirtacM. StanculI. TcaciucD. AlbertM. AlexopoulouI. ArnaoutA. BartlettJ. EngelJ. GilbertS. ParfittJ. SekhonH. ThomasG. RasslD.M. RintoulR.C. BifulcoC. TamakawaR. UrbaW. HaywardN. TimmersH. AntenucciA. FaccioloF. GraziG. MarinoM. MerolaR. de KrijgerR. Gimenez-RoqueploA-P. PichéA. ChevalierS. McKercherG. BirsoyK. BarnettG. BrewerC. FarverC. NaskaT. PennellN.A. RaymondD. SchileroC. SmolenskiK. WilliamsF. MorrisonC. BorgiaJ.A. LiptayM.J. PoolM. SederC.W. JunkerK. OmbergL. DinkinM. ManikhasG. AlvaroD. BragazziM.C. CardinaleV. CarpinoG. GaudioE. CheslaD. CottinghamS. DubinaM. MoiseenkoF. DhanasekaranR. BeckerK-F. JanssenK-P. Slotta-HuspeninaJ. Abdel-RahmanM.H. AzizD. BellS. CebullaC.M. DavisA. DuellR. ElderJ.B. HiltyJ. KumarB. LangJ. LehmanN.L. MandtR. NguyenP. PilarskiR. RaiK. SchoenfieldL. SenecalK. WakelyP. HansenP. LechanR. PowersJ. TischlerA. GrizzleW.E. SextonK.C. KastlA. HendersonJ. PortenS. WaldmannJ. FassnachtM. AsaS.L. SchadendorfD. CouceM. GraefenM. HulandH. SauterG. SchlommT. SimonR. TennstedtP. OlabodeO. NelsonM. BatheO. CarrollP.R. ChanJ.M. DisaiaP. GlennP. KelleyR.K. LandenC.N. PhillipsJ. PradosM. SimkoJ. Smith-McCuneK. VandenBergS. RogginK. FehrenbachA. KendlerA. SifriS. SteeleR. JimenoA. CareyF. ForgieI. MannelliM. CarneyM. HernandezB. CamposB. Herold-MendeC. JungkC. UnterbergA. von DeimlingA. BosslerA. GalbraithJ. JacobusL. KnudsonM. KnutsonT. MaD. MilhemM. SigmundR. GodwinA.K. MadanR. RosenthalH.G. AdebamowoC. AdebamowoS.N. BoussioutasA. BeerD. GiordanoT. Mes-MassonA-M. SaadF. BocklageT. LandrumL. MannelR. MooreK. MoxleyK. PostierR. WalkerJ. ZunaR. FeldmanM. ValdiviesoF. DhirR. LuketichJ. PineroE.M.M. Quintero-AguiloM. CarlottiC.G.Jr Dos SantosJ.S. KempR. SankarankutyA. TirapelliD. CattoJ. AgnewK. SwisherE. CreaneyJ. RobinsonB. ShelleyC.S. GodwinE.M. KendallS. ShipmanC. BradfordC. CareyT. HaddadA. MoyerJ. PetersonL. PrinceM. RozekL. WolfG. BowmanR. FongK.M. YangI. KorstR. RathmellW.K. Fantacone-CampbellJ.L. HookeJ.A. KovatichA.J. ShriverC.D. DiPersioJ. DrakeB. GovindanR. HeathS. LeyT. Van TineB. WesterveltP. RubinM.A. LeeJ.I. AredesN.D. MariamidzeA. Oncogenic signaling pathways in the cancer genome atlas.Cell20181732321337.e1010.1016/j.cell.2018.03.03529625050
     [Google Scholar]
  9. MarchettiA. FelicioniL. MalatestaS. Grazia SciarrottaM. GuettiL. ChellaA. ViolaP. PullaraC. MucilliF. ButtittaF. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.J. Clin. Oncol.201129263574357910.1200/JCO.2011.35.963821825258
     [Google Scholar]
  10. AlvarezJ.G.B. OttersonG.A. Agents to treat BRAF-mutant lung cancer.Drugs Context2019821256630899313
     [Google Scholar]
  11. O’LearyC.G. AndelkovicV. LadwaR. PavlakisN. ZhouC. HirschF. RichardD. O’ByrneK. Targeting BRAF mutations in non-small cell lung cancer.Transl. Lung Cancer Res.2019861119112410.21037/tlcr.2019.10.2232010589
     [Google Scholar]
  12. YanN. GuoS. ZhangH. ZhangZ. ShenS. LiX. BRAF-mutated non-small cell lung cancer: Current treatment status and future perspective.Front. Oncol.20221286304310.3389/fonc.2022.86304335433454
     [Google Scholar]
  13. DésageA.L. LéonceC. SwalduzA. Ortiz-CuaranS. Targeting KRAS mutant in non-small cell lung cancer: novel insights into therapeutic strategies.Front. Oncol.20221279683210.3389/fonc.2022.79683235251972
     [Google Scholar]
  14. DrostenM. BarbacidM. Targeting KRAS mutant lung cancer: light at the end of the tunnel.Mol. Oncol.20221651057107110.1002/1878‑0261.1316834951114
     [Google Scholar]
  15. BaikC.S. MyallN.J. WakeleeH.A. Targeting BRAF -mutant non-small cell lung cancer: From molecular profiling to rationally designed therapy.Oncologist201722778679610.1634/theoncologist.2016‑045828487464
     [Google Scholar]
  16. SongY. BiZ. LiuY. QinF. WeiY. WeiX. Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials.Genes Dis.2023101768810.1016/j.gendis.2022.05.00637013062
     [Google Scholar]
  17. BaharM.E. KimH.J. KimD.R. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.Signal Transduct. Target. Ther.20238145510.1038/s41392‑023‑01705‑z38105263
     [Google Scholar]
  18. MustachioL.M. Chelariu-RaicuA. SzekvolgyiL. RoszikJ. Targeting KRAS in Cancer: Promising therapeutic strategies.Cancers (Basel)2021136120410.3390/cancers1306120433801965
     [Google Scholar]
  19. ElghissassiI. InrhaounH. BoukirA. KettaniF. GamraL. MestariA. JabriL. BensoudaY. MrabtiH. ErrihaniH. Frequency and spectrum of KRAS mutations in moroccan patients with lung adenocarcinoma.ISRN Oncol.201420141410.1155/2014/19249324729895
     [Google Scholar]
  20. LoongH.H.F. DuN. ChengC. LinH. GuoJ. LinG. LiM. JiangT. ShiZ. CuiY. JinX. YaoJ. XingY. YaoM. WangK. MokT.S.K. LiuL. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples.Transl. Lung Cancer Res.2020951759176910.21037/tlcr‑20‑45533209599
     [Google Scholar]
  21. KarimiN. MoghaddamS.J. KRAS-mutant lung cancer: Targeting molecular and immunologic pathways, therapeutic advantages and restrictions.Cells202312574910.3390/cells1205074936899885
     [Google Scholar]
  22. BurnsT.F. BorghaeiH. RamalingamS.S. MokT.S. PetersS. Targeting KRAS -mutant non–small-cell lung cancer: One mutation at a time, with a focus on KRAS G12C mutations.J. Clin. Oncol.202038354208421810.1200/JCO.20.0074433104438
     [Google Scholar]
  23. JuddJ. Abdel KarimN. KhanH. NaqashA.R. BacaY. XiuJ. VanderWaldeA.M. MamdaniH. RaezL.E. NagasakaM. PaiS.G. SocinskiM.A. NievaJ.J. KimC. WozniakA.J. IkpeazuC. de Lima LopesG.Jr SpiraA.I. KornW.M. KimE.S. LiuS.V. BorghaeiH. Characterization of KRAS mutation subtypes in non–small cell lung cancer.Mol. Cancer Ther.202120122577258410.1158/1535‑7163.MCT‑21‑020134518295
     [Google Scholar]
  24. GhimessyA. RadeczkyP. LaszloV. HegedusB. Renyi-VamosF. FillingerJ. KlepetkoW. LangC. DomeB. MegyesfalviZ. Current therapy of KRAS-mutant lung cancer.Cancer Metastasis Rev.20203941159117710.1007/s10555‑020‑09903‑932548736
     [Google Scholar]
  25. LuoJ. OstremJ. PelliniB. ImbodyD. SternY. SolankiH.S. HauraE.B. VillaruzL.C. Overcoming KRAS-mutant lung cancer.Am. Soc. Clin. Oncol. Educ. Book20224211135412860
     [Google Scholar]
  26. TomasiniP. WaliaP. LabbeC. JaoK. LeighlN.B. Targeting the KRAS pathway in non-small cell lung cancer.Oncologist201621121450146010.1634/theoncologist.2015‑008427807303
     [Google Scholar]
  27. ImprotaG. ZupaA. PossidenteL. TartaroneA. PediciniP. NappiA. MolinariS. FraggettaF. VitaG. Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity.Oncol. Lett.2013551741174310.3892/ol.2013.125523761841
     [Google Scholar]
  28. HuangL. GuoZ. WangF. FuL. KRAS mutation: from undruggable to druggable in cancer.Signal Transduct. Target. Ther.20216138610.1038/s41392‑021‑00780‑434776511
     [Google Scholar]
  29. LiuJ. KangR. TangD. The KRAS-G12C inhibitor: Activity and resistance.Cancer Gene Ther.202229787587810.1038/s41417‑021‑00383‑934471232
     [Google Scholar]
  30. AdderleyH. BlackhallF.H. LindsayC.R. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.EBioMedicine20194171171610.1016/j.ebiom.2019.02.04930852159
     [Google Scholar]
  31. SkoulidisF. LiB.T. DyG.K. PriceT.J. FalchookG.S. WolfJ. ItalianoA. SchulerM. BorghaeiH. BarlesiF. KatoT. Curioni-FontecedroA. SacherA. SpiraA. RamalingamS.S. TakahashiT. BesseB. AndersonA. AngA. TranQ. MatherO. HenaryH. NgarmchamnanrithG. FribergG. VelchetiV. GovindanR. Sotorasib for lung cancers with KRAS p.G12C mutation.N. Engl. J. Med.2021384252371238110.1056/NEJMoa210369534096690
     [Google Scholar]
  32. BennaniB. GillesS. FinaF. NanniI. IbrahimiS.A. RiffiA.A. NejjariC. BenajehD.A. AbkariM.E. MartinP.M. OuafikL.H. Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer.Int. J. Biol. Markers201025417918410.5301/JBM.2010.609121161938
     [Google Scholar]
  33. MarchoudiN. Amrani Hassani JouteiH. JoualiF. FekkakJ. RhaissiH. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer.Pathol. Biol. (Paris)201361627327610.1016/j.patbio.2013.05.00423849768
     [Google Scholar]
  34. KaabouchM. ChahdiH. AzouziN. OukabliM. RharrassiI. BoudhasA. JaddiH. AbabouM. DakkaN. BoichardA. BakriY. DupuyC. Al BouzidiA. Ameziane El HassaniR. BRAFV600E hot spot mutation in thyroid carcinomas: First Moroccan experience from a single-institution retrospective study.Afr. Health Sci.20202041849185610.4314/ahs.v20i4.4034394248
     [Google Scholar]
  35. Nguyen-NgocT. BouchaabH. AdjeiA.A. PetersS. BRAF alterations as therapeutic targets in non–small-cell lung cancer.J. Thorac. Oncol.201510101396140310.1097/JTO.000000000000064426301799
     [Google Scholar]
  36. KimH.C. KangY.R. JiW. KimY.J. YoonS. LeeJ.C. ChoiC.M. Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations.OncoTargets Ther.2019126045605210.2147/OTT.S21392831440061
     [Google Scholar]
  37. NgP.K.S. LiJ. JeongK.J. ShaoS. ChenH. TsangY.H. SenguptaS. WangZ. BhavanaV.H. TranR. SoewitoS. MinussiD.C. MorenoD. KongK. DogrulukT. LuH. GaoJ. TokheimC. ZhouD.C. JohnsonA.M. ZengJ. IpC.K.M. JuZ. WesterM. YuS. LiY. VellanoC.P. SchultzN. KarchinR. DingL. LuY. CheungL.W.T. ChenK. ShawK.R. Meric-BernstamF. ScottK.L. YiS. SahniN. LiangH. MillsG.B. Systematic functional annotation of somatic mutations in cancer.Cancer Cell2018333450462.e1010.1016/j.ccell.2018.01.02129533785
     [Google Scholar]
  38. ZhangL. ZhengL. YangQ. SunJ. The evolution of BRAF activation in non-small-cell lung cancer.Front. Oncol.20221288294010.3389/fonc.2022.88294035912223
     [Google Scholar]
  39. MazieresJ. CropetC. MontanéL. BarlesiF. SouquetP.J. QuantinX. Dubos-ArvisC. OttoJ. FavierL. AvrillonV. CadranelJ. Moro-SibilotD. MonnetI. WesteelV. Le TreutJ. BrainE. TrédanielJ. JaffroM. CollotS. FerrettiG.R. TiffonC. Mahier-Ait OukhatarC. BlayJ.Y. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.Ann. Oncol.202031228929410.1016/j.annonc.2019.10.02231959346
     [Google Scholar]
  40. CardarellaS. OginoA. NishinoM. ButaneyM. ShenJ. LydonC. YeapB.Y. ShollL.M. JohnsonB.E. JänneP.A. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.Clin. Cancer Res.201319164532454010.1158/1078‑0432.CCR‑13‑065723833300
     [Google Scholar]
  41. FrisoneD. FriedlaenderA. MalapelleU. BannaG. AddeoA. A BRAF new world.Crit. Rev. Oncol. Hematol.202015210300810.1016/j.critrevonc.2020.10300832485528
     [Google Scholar]
/content/journals/cppm/10.2174/0118756921347352241112105112
Loading
First Insight into the Mutational Landscape of BRAF and KRAS Genes in Lung Cancer Patients from Morocco
Curr. Pharm. and. Per. Med. 22, E18756921347352 (2025); https://doi.org/10.2174/0118756921347352241112105112
/content/journals/cppm/10.2174/0118756921347352241112105112
/content/journals/cppm/10.2174/0118756921347352241112105112
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): BRAF; KRAS; Lung cancer; mutational landscape; NSCLC; targeted therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test